Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Victor Yang (), Tue W. Kragstrup (), Christopher McMaster (), Pankti Reid (), Namrata Singh (), Stine R. Haysen (), Philip C. Robinson () and David F. L. Liew ()
Additional contact information
Victor Yang: Level 1, North Wing, Heidelberg Repatriation Hospital, Austin Health
Tue W. Kragstrup: Aarhus University Hospital
Christopher McMaster: Level 1, North Wing, Heidelberg Repatriation Hospital, Austin Health
Pankti Reid: University of Chicago Biological Sciences Division
Namrata Singh: University of Washington
Stine R. Haysen: Aarhus University
Philip C. Robinson: University of Queensland
David F. L. Liew: Level 1, North Wing, Heidelberg Repatriation Hospital, Austin Health

Drug Safety, 2023, vol. 46, issue 11, No 1, 1049-1071

Abstract: Abstract Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from the ORAL Surveillance phase 3b/4 post-marketing requirement randomized controlled trial. In that study of patients with rheumatoid arthritis with existing cardiovascular risk, tofacitinib, the first JAKi registered for chronic inflammatory disease, failed to meet non-inferiority thresholds when compared with tumor necrosis factor inhibitors for both incident major adverse cardiovascular events and incident cancer. While this result was unexpected by many, subsequently published observational data have also supported this finding. Notably, however, such a risk has largely not yet been demonstrated in patients outside the specific clinical situation examined in the trial, even in the face of many studies examining this. Nevertheless, this signal has practically re-aligned approaches to both tofacitinib and other JAKi to varying extents, in other patient populations and contexts: within rheumatoid arthritis, but also in psoriatic arthritis, axial spondyloarthritis, inflammatory bowel disease, atopic dermatitis, and beyond. Application to individual patients can be more challenging but remains important to harness the substantive potential of JAKi to the maximum extent safely possible. This review not only explores the evolution of the regulatory response to the signal, its informing data, biological plausibility, and its impact on guidelines, but also the many factors that clinicians must consider in navigating cardiovascular and cancer risk for their patients considering JAKi as immune-modulating therapy.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01333-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:46:y:2023:i:11:d:10.1007_s40264-023-01333-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01333-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().